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Abstract: Melanoma is a lethal tumor because of its severe metastatic potential, and 
serine/threonine-protein kinase B-raf inhibitors (BRAFi) are used in patients harboring 
BRAF-mutation. Unfortunately, BRAFi induce resistance. Therefore, we tested the activity of 
onconase (ONC), a cytotoxic RNase variant, against BRAFi-resistant cells to re-establish the efficacy 
of the chemotherapy. To do so, an A375 dabrafenib-resistant (A375DR) melanoma cell 
subpopulation was selected and its behavior compared with that of parental (A375P) cells by 
crystal violet, 5-Bromo-2’-deoxyuridine incorporation, and cleaved poly(ADP-ribose) polymerase 1 
(PARP1) western blot measurements. Then, nuclear p65 Nuclear Factor kappaB (NF-κB) and IκB 
kinases-α/β (IKK) phosphorylation levels were measured. Gelatin zymography was performed to 
evaluate metalloproteinase 2 (MMP2) activity. In addition, assays to measure migration, invasion 
and soft agar colony formation were performed to examine the tumor cell dissemination 
propensity. ONC affected the total viability and the proliferation rate of both A375P and A375DR 
cell subpopulations in a dose-dependent manner and also induced apoptotic cell death. Among its 
pleiotropic effects, ONC reduced nuclear p65 NF-κB amount and IKK phosphorylation level, as 
well as MMP2 activity in both cell subpopulations. ONC decreased cell colony formation, 
migration, and invasion capability. Notably, it induced apoptosis and inhibited colony formation 
and invasiveness more extensively in A375DR than in A375P cells. In conclusion, ONC successfully 
counteracts melanoma malignancy especially in BRAFi-resistant cells and could become a tool 
against melanoma recurrence. 
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1. Introduction 
Malignant melanoma is a highly aggressive skin cancer that has shown increasing incidence 
and mortality over recent decades [1]. Melanoma is characterized either by a high degree of 
plasticity or by severe metastatic potential, and the conventional therapies used in clinics are 
time-limited and far from being successful [2]. Indeed, although BRAF inhibitors (BRAFi) are the 
most potent therapeutic drugs approved to counteract the melanoma cases displaying 
BRAF-mutated genotype [3], their use is not decisive because patients acquire resistance after 8–10 
months of treatment [2,4]. In order to investigate the mechanisms involved in the resistance to 
dabrafenib or vemurafenib BRAFi, several studies have been addressed to select the resistant 
melanoma cell populations and better characterize their key features [5–10]. It has been recently 
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reported that A375 melanoma cells become resistant to vemurafenib upon acquiring a cancer stem 
cells (CSC) phenotype and, consequently, the ability to form melanospheres [11]. Indeed, melanoma 
CSC can be identified because they display either undifferentiation or embryonic state markers, such 
as NGF receptor , Prominin-1 (CD133), Transcription Factor Sox2, Octamer-binding protein 4, and 
Homeobox protein NANOG (NANOG) [11]. Moreover, CSC are a subpopulation of tumor cells that 
are extremely malignant, since CSC can infiltrate and colonize other tissues. It was reported that, 
during vemurafenib treatment, resistant cells rapidly led to tumor onset in mice implanted with a 
mixture of sensitive and BRAFi-resistant A375 melanoma cells. On the contrary, a tumor does not 
grow in mice treated with the same drug but implanted with only A375 vemurafenib-sensitive cells 
[10]. Hence, drug-resistant cells can quickly lose their adherence ability and gain both migratory and 
invasive capability. This also occurs through the penetration of the cells into the extracellular matrix 
(ECM), an event that leads to the formation of new tumors in other body sites [12]. Considering that 
ECM acts as a mechanical barrier against tumor-cell mobility, its degradation becomes crucial in 
supporting the tumor dissemination process. In this regard, it is well known that matrix 
metalloproteinases (MMPs) cause ECM damage and that high levels of MMPs are secreted by 
melanoma cells [13,14]. Therefore, the strategy of blocking melanoma cell migration, invasion, and 
progression could be aided by drugs inhibiting MMPs activity. Moreover, intracellular signals, such 
as the one represented by the Wnt/β-catenin pathway, play an important role in melanoma 
pathogenesis and progression [15,16]. Indeed, Sinnberg et al. demonstrated that β-catenin is 
involved in the melanoma acquired resistance to vemurafenib [17]. Hence, the nuclear localization of 
β-catenin could be a specific determinant for the cell resistance to BRAFi. 
In order to find new therapeutic strategies against drug resistance, several recent works have 
focused their investigations on the combination of BRAFi with synthetic compounds or with natural 
products [14,18–20]. In a previous report, we demonstrated that nanomolar concentrations of the 
enzyme onconase (ONC) exert both cytostatic and cytotoxic activities against A375 melanoma cell 
line [21]. In addition, ONC is known to counteract the viability of two conjunctival melanoma cell 
lines [22]. This protein is a secretory, 11.8 kDa basic enzyme extracted from frog oocytes that exerts 
ribonucleolytic activity and shows the typical fold of the pancreatic-type RNases, as does RNase A 
[23,24]. Importantly, ONC displays a remarkable antitumor action [24,25] because it is efficiently 
internalized in the malignant cells. The specificity of ONC for cancer cells depends on its high 
number of basic charges that eases its binding to the tumor cell surface, which in turn displays a 
higher amount of negative charges than normal cells [26]. ONC can enter cells by endocytosis in the 
early endosome and, finally, reaches the cytosol and evades the intracellular RNase inhibitor, thus 
exerting a cytotoxic action [26]. It is a multi-target drug, since its ribonucleolytic activity against 
tRNA and miRNA causes multiple biological effects by up- or down-regulating the expression of 
several genes [26,27]. Notably, ONC has been used as a therapeutic agent in phase II and III clinical 
trials against non-small cell lung carcinoma and unresectable mesothelioma, respectively [27]. 
Although being a heterologous protein, low immunogenicity levels have been reported in clinic, as 
well as minor side effects other than nephrotoxicity that disappears upon halting ONC 
administration [27]. In malignant mesothelioma, ONC inhibits Tumor Necrosis Factor-alpha 
(TNFα)-elicited NF-κB nuclear translocation and reduces MMP9 activity, as well as cell invasiveness 
[28]. In the same neoplasia, the ONC-elicited NF-κB downregulation is caused by changes in the 
expression levels of two specific miRNAs. In this way, ONC decreases colony formation, motility, 
invasion, and proliferation of mesothelioma cells [29]. Notably, we have recently shown that this 
RNase inhibits NF-κB DNA-binding in A375 melanoma cells as well [21]. 
In the present work, we analyze the ability of ONC to affect the viability of A375 cells which 
have acquired resistance to dabrafenib (A375DR), in comparison with parental (A375P) cells. 
Therefore, the impact of ONC on cell proliferation, apoptosis, cell migration, and invasion 
capability, as well as on the inhibition of NF-κB nuclear translocation and of MMP2 activity, have 
been compared here within the two A375 cell subpopulations. 
2. Results 
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2.1. ONC Strongly Affects Cell Viability of both Parental and Dabrafenib Resistant A375 Cells 
Considering that drug resistance is one of the main factors limiting the efficacy of melanoma 
therapy, the BRAF-mutated-A375 human melanoma cell line was cultured with gradually increasing 
concentrations of dabrafenib until a cell subpopulation grew in the constant presence of 5 µM of this 
drug. Then, the resulting dabrafenib-resistant A375DR cells were maintained for six months under a 
selective pressure of the drug. After this period, dabrafenib sensitivity was measured by crystal 
violet assay in both A375P and A375DR cell subpopulations that were treated with dabrafenib 
concentrations ranging from 1 to 50 nM. As shown in Figure 1a, A375P cells were highly sensitive to 
dabrafenib, with IC25 and IC50 of 1.2 and 2.7 nM, respectively. Instead, the A375DR cell viability was 
not significantly affected up to 20 nM drug concentration, reaching IC25 only at 44 nM. Moreover, its 
relative IC50 can be only extrapolated, reaching a value that definitely overpasses 5 µM, i.e., the 
maximal dabrafenib concentration used in our experiments. Importantly, the differences detected by 
comparing the data collected from A375P and A375DR cells were statistically significant for each 
concentration tested (Figure 1a: p = 0.02, p = 0.0002, p = 0.00008, p = 0.0001, p = 0.0004, and p = 0.0001, 
for 1, 2, 5, 10, 20, and 50 nM dabrafenib, respectively). 
In agreement with a recent paper published by our group [21], low ONC concentrations 
strongly reduced the viability of A375P cells (Figure 1b). In the present work we compare, instead, 
the effect of ONC registered on parental versus dabrafenib-resistant subpopulations of the same cell 
line. Figure 1b shows that the viability of both cell subpopulations is reduced to a similar extent, and 
in a dose-dependent manner, after a 72 h culture with ONC, with calculated IC50 values of 0.40 and 
0.32 µM for A375P and A375DR cells, respectively. No statistically significant differences in the 
sensitivity to ONC emerged within the two cell subpopulations, although the mean viability 
reduction of A375DR cells was lower than that of parental ones for each concentration tested (Figure 
1b). 
2.2. ONC Does not Affect Cell Viability of Normal Melanocytes 
To evaluate the specificity of ONC activity against melanoma cells, we also measured the 
sensitivity of normal human epidermal melanocytes (NHEM) to this RNase variant. NHEM cells 
were incubated for 72 h with the two ONC concentrations that were the most effective against 
malignant cells (0.5, 1 µM), and also with 2 and 4 µM ONC (Figure 1b). By the crystal violet assay, 
we found no reduction in cell viability either at 0.5 or 1 µM ONC concentration (Figure 1b, cyan 
dots; NHEM versus A375P, p = 0.00004 and p = 0.00002 for 0.5 and 1 µM ONC, respectively). 
Moreover, the maximal ONC dose (4 µM), tested exclusively in the NHEM cells, reduced their 
viability only by 14%. Hence, we conclude that ONC displays quite high cytostatic and cytotoxic 
effects only in melanoma cells, while not doing so in normal melanocytes. 
2.3. ONC Decreases the Proliferation Rate of both A375P and A375DR Cell Subpopulations 
We performed a 5-Br-2’-deoxyuridine (BrdU) incorporation assay to identify whether in both 
cell subpopulations the viability reduction elicited by ONC might depend on the cell proliferation 
rate or, instead, on a cell mass decrease consequent to cell death. After 24, 48, and 72 h culture with 
ONC, an additional 4 h BrdU incubation showed a concentration-dependent reduction of its 
incorporation in both A375P and A375DR cells. Nevertheless, ONC-treated A375DR cells showed a 
smaller reduction of BrdU incorporation level than A375P ones, as is clearly visible in Figures 2a–c. 
In these panels, data have been normalized to each parental or dabrafenib-resistant ONC-free 
control. All time-point differences emerging by comparing the two ONC-treated cell subpopulations 
are statistically significant), except for 1 µM ONC at 72 h (A375P versus A375DR for 0.5 and 1 µM 
ONC, respectively: 24 h, p = 0.05, p = 0.04; 48 h, p = 0.02, p = 0.05; and 72 h, p = 0.03, n.s.). Although not 
visible in Figure 2, we underline that also ONC-free A375DR cells appeared to be about 50%–70% 
less proliferating, as a function of time, than ONC-free A375P cells. 
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In the end, these data indicate that ONC decreases the proliferation rate of both A375P and 
A375DR cells, although this reduction is more evident in A375P, probably because these cells 
display a higher replication rate than the A375DR subpopulation. 
 
Figure 1. Effect of dabrafenib or onconase (ONC) on the viability of melanoma A375 and of normal 
human epidermal melanocytes (NHEM) cells. (a) A375P (blue dots) and A375DR (red dots) cell 
viability detected after 72 h incubation with increasing concentrations of dabrafenib. For each 
dabrafenib concentration tested (panel a), all A375P versus A375DR comparisons are statistically 
significant (see text). (b) cell viability of A375P (blue dots), A375DR (red dots), and NHEM (cyan dots) 
after 72 h incubation with increasing concentrations of ONC. Statistically significant differences are 
present (p < 0.0001) between NHEM versus A375P or A375DR cells, either at 0.5 or 1 µM ONC, while 
not between the two A375 cell subpopulations at all ONC concentrations tested. All values reported are 
the average of four to five independent experiments, each performed in six replicates, ± S.D. 
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Figure 2. Effect of ONC in the proliferation rate of the two A375 cell subpopulations. (a) 24 h, (b) 48 
h, and (c) 72 h measurement of cell proliferation performed with 5-Br-2’-deoxyuridine (BrdU) 
incorporation in A375P (blue dots) or A375DR (red dots) cells after being incubated with 0.5 or 1.0 
µM ONC, in comparison with ONC-free controls. The BrdU data are normalized to each control 
sample to better visualize the lower reduction of the proliferation rate elicited by ONC in A375DR 
than in A375P cells. Values reported are the average of four independent experiments, each 
performed in triplicate, ± S.D. * p < 0.05; ns, not statistically significant. 
2.4. ONC Induces Apoptotic Cell Death Mainly in A375DR Cells 
Most of the cells treated for 72 h with 1 µM ONC turned out to be detached from the plate, 
indicating that cell death actually took place. Furthermore, this event was more evident in A375DR 
than in A375P cells. To verify whether ONC-treated cells underwent apoptosis, the expression level 
of cleaved PARP1 was measured. In Figure 3a, a representative western blot (WB) is shown, while in 
Figure 3b the average expression level of cleaved PARP1 relative to four independent experiments, 
and measured after β-actin normalization, is reported. ONC-free A375DR cells showed higher 
cleaved PARP1 expression level than ONC-free A375P ones (p = 0.01). The amount of cleaved PARP1 
increased significantly in all ONC-treated cell samples if compared to each ONC-free one (p = 0.002 
and p = 0.005 for A375P and A375DR, respectively), thus confirming that 1 µM ONC induced the 
apoptotic death of A375 cells. Remarkably, ONC-treated A375DR cells showed an impressive 
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increase of cleaved PARP1 amount in comparison with ONC-free A375DR cells, but also with 
ONC-treated A375P (ONC-treated A375DR versus ONC-treated A375P, p = 0.01). In conclusion, 
although ONC-treated A375DR cells showed a lower reduction in the cell proliferation rate than 
ONC-treated A375P cells (see Figure 2), they appear more prone to undergoing apoptotic cell death 
than the parental ones (Figure 3b). 
 
Figure 3. ONC effects in the amount of cleaved PARP1, nuclear p65, and the phosphorylation level of 
IκB kinases-α/β (p-IKK) in both A375 cell subpopulations. (a) Representative WB performed with 
antibodies recognizing PARP1, p65 in the nucleus and the p-IKK. The hybridization with β-tubulin of 
either the nuclear or the whole cell protein extractsWB membranes has been performed to exclude the 
cytosolic contamination in the nuclear extracts. β-actin expression levels were used as the internal 
control; (b) Fold-change for the quantification of the cleaved PARP1 WB bands detected after 
incubating both cell subpopulations (A375P, blue bars; A375DR, red bars) in the presence (diagonal 
hatched bars) or absence (no hatching) of ONC; and (c) Fold-change for the quantification of p65 
nuclear localization and p-IKK WB bands detected after incubating both cell subpopulations in the 
presence or absence of ONC: Data reported, obtained after β-actin normalization, are the average of 
four independent WB experiments ± S.D. All differences registered in panels b and c between ONC-free 
and ONC-treated samples are statistically significant in both cell subpopulations. * p < 0.05, ** p < 0.01. 
2.5. ONC Affects NF-κB Activation in both A375 Cell Subpopulations 
As measured by WB, ONC-free A375P cells showed detectable amounts of p65 NF-κB localized 
in the nucleus, and this expression level was even increased in ONC-free A375DR cells (Figure 3a,c, 
p = 0.05), suggesting that NF-κB was activated in both ONC-free subpopulations. Instead, either 
A375P or A375DR cells treated with 1 µM ONC showed a significantly decreased nuclear p65 level 
(Figures 3a,c; p = 0.04 and p = 0.008, for A375P and A375DR, respectively). To exclude the 
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contamination of nuclear extracts by cytosolic proteins, WB membranes containing either the 
nuclear or the whole cell protein extracts were hybridized with the β-tubulin antibody. As shown in 
Figure 3a, a large amount of β-tubulin was present in the whole cell protein extracts (right panel), 
while only very low amounts were visible in the nuclear protein extract samples (left panel). This 
suggests that the nuclear protein extracts were pure enough to consider the nuclear p65 levels 
detected reliable. To further confirm this result, we measured the phosphorylation level of IκB 
kinases-α/β (p-IKK) that triggers NF-κB activation. We found that these kinases follow the same 
trend shown by p65. Indeed, the detected p-IKK level was higher in ONC-free A375DR than in 
A375P cells (p = 0.008), while ONC decreased its amount especially in A375DR cells (Figures 3a,c; p = 
0.04 and p = 0.001, for A375P and A375DR, respectively). Therefore, our data suggest that ONC 
reduces p65 NF-κB nuclear localization by inhibiting IκB kinases-α/β (IKK) phosphorylation. 
2.6. The A375DR Cell Subpopulation Displays the Presence of CSC Biochemical Markers 
A375DR cells display a lower BrdU incorporation level than their BRAFi-sensitive A375P 
counterpart. This behavior may suggest that CSC clonal expansion occurred in this subpopulation 
[5,30,31]. The mRNA expression levels of CD133, a transmembrane glycoprotein expressed on the 
surface of both normal and cancer stem cells, and of NANOG, a transcription regulator factor 
involved in the maintenance of an embryonic stem cell state, were measured by real-time (RT) qPCR 
in both A375P and A375DR ONC-free controls. CD133 and NANOG mRNAs showed in A375DR 
cells a 2.1- and 2.4-fold increases, respectively, in comparison to the relative expression levels 
detected in A375P, with the amount of the mRNA of TATA box binding protein (TBP) used here as 
the internal standard (Figure 4a; CD133, p = 0.009 and NANOG, p = 0.04). These results demonstrate 
that A375DR cells display a higher gene expression level of both CD133 and NANOG markers of 
undifferentiation and embryonic stem cells than A375P ones. In addition, the protein amounts of the 
same CSC markers detected by WB were increased in A375DR cell subpopulation (Figure 4b), 
although these data need to be further examined in situ by immunofluorescence of flow cytometric 
analysis. 
Thereafter, the protein expression levels of epithelial-to-mesenchymal transition (EMT) markers 
were measured in both cell subpopulations. Representative WB experiments showing a higher 
expression level of N-cadherin and nuclear β-catenin in ONC-free A375DR than in ONC-free A375P 
cell subpopulations are reported in Figure 4b. Our results show that A375DR cells express high 
levels of CSC mRNA expression markers, such as CD133 and NANOG. This subpopulation 
undergoes EMT as suggested by the increase of nuclear β-catenin and N-cadherin protein levels. 
Finally, we confirmed that A375DR cells escape from BRAF inhibition by activating the Extracellular 
Signal-Regulated Kinase 1 and 2 (ERK1/2) pathway, as shown by the increase of ERK1/2 
phosphorylation level (Figure 4b). 
 
Figure 4. Expression levels of malignancy markers on A375DR versus A375P cells. (a) mRNA 
expression levels of CD133 and NANOG. Values were measured with RT-qPCR in ONC-free A375P 
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(blue bars) and A375DR (red bars) cells, respectively. Average data ± S.D. refer to three independent 
experiments, each performed in triplicate; * p < 0.05, ** p < 0.01; and (b) representative WB showing 
the expression levels of CD133, NANOG, N-cadherin, nuclear β-catenin, p-ERK1/2, and β-actin (the 
latter for normalization) relative to the two ONC-free A375 cell subpopulations. 
2.7. ONC Reduces the Ability of both A375P and A375DR Cells to Form Soft Agar Colonies 
Anchorage-independent growth measurements indicate how cells can grow independently of 
the presence of a solid surface support. Figure 5a shows that, in soft agar, ONC-free A375P cells 
formed a higher number of colonies than ONC-treated ones (p = 0.0008). In addition, the number of 
ONC-free A375DR colonies formed was very high, while the number of visible colonies approached 
zero upon 1 µM ONC incubation (p = 0.0001). A significant difference was found also between the 
two ONC-free cell subpopulations (p = 0.009). In Figure 5b, representative images of what occurred 
in soft agar are shown. 
A characteristic of stem cells is their capability of forming clones in soft agar [32]. Hence, the 
remarkable malignancy of A375DR cells is further demonstrated here by their ability to form a high 
number of colonies in soft agar assay. Importantly, this ability was suppressed by ONC to a greater 
extent in A375DR than in A375P cells. 
 
Figure 5. ONC effect on the colony formation of the two A375 cell subpopulations. (a) Number of 
colonies produced in soft agar by A375P (blue bars) and A375DR (red bars) cells after 72 h incubation 
with or without 1 µM ONC. After ONC treatment, cells were detached, counted, and cultured for 21 
days in the medium containing 0.6% agar. Data reported are relative to three independent replicates 
± S.D. All differences detected were statistically significant, ** p < 0.01; and (b) Representative images 
of the colonies formed by A375P and A375DR cells in the presence or absence of ONC. 10× 
magnification images were taken with a Zeiss Axio Vert. A1 AxioCAM/cm−1 60N-C1”camera. 
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2.8. ONC Reduces Either Cell Migration Rate or Invasion 
A wound-healing assay was performed to measure the cell migration ability of both A375P and 
A375DR subpopulations in the presence or absence of ONC. Notably, the time necessary to close the 
wound was different: In particular, A375DR cells migrated and proliferated more slowly than the 
A375P counterpart. Indeed, 1 µM ONC remarkably reduced the migration rate either of A375P or of 
A375DR cells, as is visible in Figures 6a,b, respectively. The c panel of Figure 6 shows instead the 
frames recorded either at the beginning or at the end of the test performed with ONC-free or 
ONC-treated A375DR cells. 
 
Figure 6. Wound closure time-course of the two A375 cell subpopulations after they suffered 
scratching. (a) A375P and (b) A375DR cells; and (c) Initial (t0) and final (t3240 min) frames of ONC-free 
or 1 µM ONC-treated A375DR cells. 4× magnification images were recorded with the EVOS FL Auto 
Cell Imaging System. 
In order to verify whether A375 cells can acquire an invasive phenotype, we examined the effect 
of ONC on the ability of A375DR cells to migrate through the Matrigel. Cells were seeded in the 
upper chamber of a Transwell plate, and complete Dulbecco’s Modified Eagle’s Medium (DMEM) 
was added to the lower chamber as a chemo-attractant. Then, the invading cells were stained and 
analyzed after 48 h: Both subpopulations invaded the Matrigel, and ONC-free A375DR cells showed 
only a small and not significant increase in their invasion potential with respect to the ONC-free 
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A375P subpopulation. Instead, the incubation with 1 µM ONC caused a remarkable 33% reduction 
in the A375DR cell-invasion capability (p = 0.008), while a lower and not statistically significant 
decrease was found in ONC-treated A375P cells, as shown in Figure 7. 
 
Figure 7. ONC effect on the invasion potential of the two A375 cell subpopulations. A375P (blue 
bars) and A375DR (red bars) cells treated (diagonal hatched bars), or not (no hatching) with 1 µM 
ONC for 72 h. Then, cells were detached, counted and seeded in a Transwell plate. After 48 h, they 
were stained and quantified in the Tecan NanoQuant Infinite M200 Pro Plate reader, as reported in 
the Materials and Methods Section. ** p < 0.01, ONC-treated versus ONC-free A375DR cells. The 
other differences were not statistically significant. 
2.9. ONC Reduces MMP2 Activity in both A375P and A375DR Cells 
Both subpopulations were cultured for 48 h with or without 1 µM ONC. Thereafter, cells were 
serum-starved for 30 h and the conditioned media collected to measure the MMP2 activity by gelatin 
zymography. The results shown in Figures 8a,b demonstrate that ONC decreases MMP2 activity at a 
similar and remarkable extent either in A375P or in A375DR cells (p = 0.001 and p = 0.0006 for A375P 
and A375DR, respectively). 
 
Figure 8. ONC reduced matrix metalloproteinase (MMP)2 activity in both cell subpopulations. (a) 
Representative gelatin-zymography for the evaluation of MMP2 activity; and (b) intensity of the 
digested bands measured with the Image-J software (A375P, blue bars; A375DR, red bars). Values 
Int. J. Mol. Sci. 2019, 20, 5980 11 of 19 
 
reported are the average of four independent experiments ± S.D. All differences in MMP2 activity 
found within ONC-treated cells (diagonal hatched bars) and each relative ONC-free control (not 
hatched) are statistically significant in both cell subpopulations, ** p < 0.01. 
3. Discussion 
Targeted therapy against melanoma performed with dabrafenib or vemurafenib BRAFi in 
patients that harbor BRAF mutations is initially effective but subsequently fails because alternative 
tumor-growth-inducing pathways are activated. Consequently, resistance to BRAFi is a commonly 
acquired event in melanoma [33]. In the present study, the aggressive BRAF-mutated A375 human 
melanoma cell line was used to pave the way for a more effective therapeutic strategy. A 
subpopulation of A375DR cells was selected after inducing a six-month-long pressure with the 
constant presence of dabrafenib in the culture medium. The high adaptive/plasticity features of this 
melanoma cell type favor the selection of more resistant malignant tumor cells expressing stem-like 
traits that arise when they remain in contact with this drug for a long period. Indeed, A375DR cells 
showed higher phosphorylated levels of ERK1/2 than A375P ones (Figure 4b), proving that ERK 
pathway reactivation occurs, in line with other literature data [5,33,34]. In addition, A375DR cells 
display both higher CD133 and NANOG gene and protein expression levels than A375P ones (Figure 
4a). We recall here that an upregulation of the CD133 marker has been recently associated with the 
capability of forming spheres in culture, a feature that characterizes tumor stem cells [11,31,35]. 
Indeed, A375DR cells showed here a higher ability to form colonies in soft agar than A375P ones, in 
confirmation of the data presented by Cordaro et al. [5]. Moreover, the NANOG upregulation 
detected suggests that A375DR cells acquired pluripotency. This result, along with N-cadherin and 
β-catenin increases, indicates that mesenchymal features are present in A375DR cells. As reported by 
Grichnik et al., melanoma CSC display either small size or a low proliferative rate but are still able to 
initiate a rapidly proliferating cell progeny [36]. Indeed, A375DR cells are less proliferative than 
A375P, as shown by the BrdU incorporation assay (Figure 2). For this reason, A375DR cells may be 
less affected by ONC cytostatic activity. In this regard, it had been previously reported that both 
vemurafenib and encorafenib BRAFi induce senescence in melanoma cells [37,38]. Therefore, it is 
also possible that a part of the A375DR cell subpopulation did not proliferate since it became 
senescent and could not respond to the ONC anti-proliferative effect. Importantly, although we 
found no statistically significant differences in the reduction of the total cell viability within the two 
ONC-treated A375 subpopulations, the high expression level of cleaved PARP1 found in A375DR 
cells indicates that ONC elicits a massive apoptotic cell death in this subpopulation. Hence, if a 
balance between ONC cytostatic and cytotoxic effects seems to take place in parental cells, a switch 
from an anti-proliferative effect toward the induction of apoptotic cell death is clearly visible in 
A375DR ones. It is worth noting that a significant difference in the expression of cleaved PARP1 is 
also detectable between the ONC-free samples of the two cell subpopulations. Therefore, A375DR 
control cells should be more prone to undergoing apoptotic cell death than A375P, while our results 
suggest that this unusual propensity is greatly strengthened by ONC. 
Indeed, ONC could be more effective in drug association therapy, since it enhances tumor cell 
sensitivity to several cytotoxic agents displaying different mechanisms of action [21,39,40]. The 
molecular mechanisms underlying ONC cytotoxicity are linked to its ribonucleolytic activity, since 
enzymatically inactive variants of this RNase are not cytotoxic [24,41]. Moreover, ONC displays 
pleiotropic activities because it exerts multi-target actions: In fact, its preferential intracellular targets 
are tRNAs, although its cytostatic/cytotoxic effects are not ascribable to a generalized protein 
synthesis inhibition [42]. Furthermore, ONC degrades noncoding RNAs, and, especially, miRNAs 
[29,39,43]. Indeed, Goparaju et al. demonstrated that ONC modulates the expression of both 
hsa-miR-30c and hsa-miR-15 that, in turn, cause the inhibition of p50 NF-κB expression and finally 
reduce pleural mesothelioma malignancy [29]. The propensity of ONC to target miRNAs may justify 
the large effects exerted on the regulation of gene expression [44]. Again, other papers indicated that 
ONC inhibits NF-κB activity in both adherent and non-adherent tumor cells [28,45], including A375 
ones, as recently reported by our group [21]. In the present work, we found a high p65 NF-κB 
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expression level especially in the nuclear extracts of A375DR cells, but this level was reduced upon 
ONC administration (Figure 3c). Although the associated molecular mechanisms have not been 
completely elucidated yet, the ONC effect on the IKK phosphorylation has been clearly detected 
here. Finally, ONC is known to exert different effects on several intracellular targets [44], and its 
activity on tumor cells likely depends on the up- or down-regulation balance of many proteins. 
Therefore, additional proteomics, phospho-proteomics, and miRNASeq approaches could better 
elucidate these molecular mechanisms of action. 
Another aspect to be highlighted is the effect of ONC on A375 tumor cell colony formation, cell 
migration, and invasion (Figures 5, 6 and 7, respectively). A375DR ONC-free cells formed more 
colonies in soft agar than ONC-free A375P ones, but the effect of 1 µM ONC is very impressive in the 
resistant cell subpopulation: Indeed, very few A375DR cells and colonies were present in soft agar 
upon ONC incubation, suggesting that the effect of ONC was potentiated by a preliminary 
prolonged treatment with dabrafenib. Instead, the reduction of the colony number detected upon 
ONC incubation was less remarkable in A375P cells. Again, the cell migration rates of the two A375 
subpopulations measured in the wound healing assay were different, indicating that different times 
are necessary to close the scratch introduced in the cell monolayer. However, the 1 µM ONC 
incubation reduced the migration of either A375P or A375DR cells, as compared to each relative 
ONC-free control. As regards the invasion assay, no significant differences were found between the 
two ONC-free A375P and A375DR counterparts in the ability to cross the Matrigel, in line with data 
reported by Fratangelo et al. [46]. On the contrary, 1 µM ONC induced a 33% significant reduction of 
the invasion capability in A375DR cells in comparison with its ONC-free control. Both cell migration 
and invasion are processes involved in the ability of cells to carry out adhesion and proteolytic 
degradation of tissue barriers [12–14]. Then, the invasion tendency of melanoma cells, and their 
consequent ability to distribute cellular clones into the metastasis sites are linked to ECM digestion. 
In addition, the elevated levels of MMPs secreted in ECM by malignant melanoma cells are 
important determinants in this process. Among several MMPs, MMP2 and MMP9 are crucial 
because they degrade type IV collagen, the major ECM component [47]. Using RNA-interference, a 
causal role of MMP2 in invasion had already been demonstrated in human retinal microvascular 
cells [48], in human extravillous trophoblast [49] and in two hepatocellular carcinoma cell lines [50]. 
The MMP2 activity measured here in both A375 cell subpopulations with gelatin zymography was 
strongly reduced by 1 µM ONC (Figure 8). Significantly, Nasu and colleagues demonstrated that 
ONC is a potent inhibitor of NF-κB activity in malignant mesothelioma, suggesting that the ONC 
blockage of NF-κB activation leads to the inhibition of MMP9 secretion and of its consequent 
invasiveness [28]. Again, berberine is also known to inhibit cell viability, as well as migration and 
invasion of both sensitive and BRAFi-resistant A375 cells, and these effects were associated with a 
reduction of MMPs activity and with the inhibition of NF-κB and of other signaling pathways [20]. 
Therefore, all these literature data [20,28] are in line either with the NF-κB nuclear level reduction or 
with the MMP2 activity inhibition observed in our cell system. 
In conclusion, besides its intrinsic cytostatic/cytotoxic effects exerted on parental A375 
melanoma cells, ONC significantly enhances its antitumor efficacy by triggering apoptosis in cells 
that were pre-treated with other drugs. Furthermore, the apoptotic cell death driven by ONC occurs 
either if a previous treatment did not induce resistance [21] or, as shown in the present work, if the 
cells had already lost their sensitivity to the cytotoxic effect of a BRAFi. Moreover, being able, in 
addition to its cytotoxic effect, to counteract both cell migration and invasion by affecting both 
NF-κB nuclear localization and MMP2 activity, ONC must certainly be regarded as an important 
tool against tumor metastasis onset. 
Last, but not least, we recall that Reck et al. reported a safe and feasible randomized phase III 
study centered on ONC and doxorubicin (DOX) therapy of unresectable malignant mesothelioma. In 
this study, however, patients had a significant advantage for survival only when they were 
previously treated with DOX before they were given ONC [51]. Therefore, the highest sensitivity to 
ONC of A375DR cells found in our work is in line with this important clinical result [51]. 
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4. Materials and Methods 
All chemicals, solvents, and buffers were from Sigma-Aldrich (Milan, Italy), unless noted 
otherwise. 
4.1. ONC Expression and Purification 
The plasmid encoding for recombinant ONC (pcDNA-ONC) was kindly provided by Prof. D. 
Picone (University of Naples, Federico II, Italy). ONC was expressed in E. coli, and extracted and 
refolded from inclusion bodies. Finally, it was purified following the protocol described by 
Notomista et al. [52]. Met (-1) was removed by incubating at 37 °C a 0.3 mg/mL ONC solution in 0.2 
M potassium phosphate, pH 8.0, containing 20 µM ZnSO4, with P. aeruginosa aminopeptidase (AAP) 
at an AAP:ONC = 1:1000 molar ratio. The reaction was blocked after 96 h by adding 0.01 M EDTA, 
final concentration. Each reaction step was monitored by analyzing the products with SDS-PAGE 
under reducing conditions. The final chromatographic purification was performed after the removal 
of the Met (-1) residue with a Superdex 75 HR 10/300 SEC column attached to an ÄKTA-FPLC 
system (GE-Healthcare, Little Chalfont, UK) [53]. Then, the accuracy of ONC expression was 
assessed with circular dichroism in a Jasco J-710 spectropolarimeter (Jasco Europe, Cremella (LC), 
Italy), while the actual Met (-1) removal was detected with Mass Spectrometry (MS) into a Ground 
Steel MALDI target plate of a Bruker Ultraflextreme MALDI-TOF/TOF instrument (Bruker Daltonics, 
Billerica, MA, USA) of the “Centro Piattaforme Tecnologiche” (CPT) of the University of Verona, 
Italy. Finally, with ONC being a pancreatic-type RNase [52,53], its actual enzymatic activity was 
measured against yeast RNA as a substrate, following the method described by Kunitz [54]. 
4.2. Cell Cultures 
Normal human epidermal melanocytes and human melanoma A375 cell lines (ATCC, 
Manassas, VA, USA), were separately cultured at 37 °C in high glucose DMEM (Gibco, BRL 
Invitrogen Corp., Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, BRL 
Invitrogen Corp., Carlsbad, CA, USA), 1% Antibiotic Antimycotic Solution (Gibco, BRL Invitrogen 
Corp., Carlsbad, CA, USA), and in a 5% CO2 humidified atmosphere. 
The parental human melanoma A375P cell line was induced to generate dabrafenib resistance 
(DR) with the aim of selecting a A375DR subpopulation: To do so, A375 cells were cultured at 37 °C 
with concentrations of dabrafenib (Selleckchem, Aurogene, Rome, Italy) that gradually increased 
from 1 nM up to 5 µM until a subpopulation grew in the constant presence of this maximal drug 
concentration. Subsequently, A375DR cells were maintained in culture with 5 µM dabrafenib for six 
months. Both A375P and A375DR subpopulations were mycoplasma tested (negative) every three 
months. 
4.3. Cell Viability Assay 
NHEM and both dabrafenib-sensitive parental, A375P, and A375 DR cell subpopulations were 
seeded in a 96-well plate (2.9 × 103 cells/well). After 24 h culture, A375 cells were incubated with 
different concentrations of dabrafenib or of ONC, and harvested after 72 h. In a parallel experiment, 
NHEM cells were treated with ONC to compare their cell viability with the ones of both A375 
subpopulations. In the experiments performed with A375DR cells, dabrafenib was removed from 
the culture medium one day before starting the 72 h incubation with ONC or dabrafenib. To 
measure cell viability, each cell sample was washed at the end of the treatment with 1× PBS solution 
(Gibco BRL Invitrogen Corp., Carlsbad, CA, USA), and stained for 5 min with 0.75% crystal violet 
powder dissolved in 8% formaldehyde and 50% ethanol. Crystal violet was solubilized in PBS/1% 
SDS solution, and OD595 measured in a plate reader (Tecan NanoQuant Infinite M200 Pro, Tecan 
Group Ltd., Männedorf, Switzerland). Six replicates were performed for each condition/time point. 
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4.4. 5-Br-2’-Deoxyuridine Cell Proliferation Assay 
Cell proliferation was assessed with a colorimetric immunoassay based on the measurement of 
BrdU incorporation during DNA synthesis. A375P or A375DR cells were seeded in 96-well plates 
(2.9 × 103 cells/well). After 24 h, cells were incubated with or without 0.5 or 1 µM ONC for 24, 48, or 
72 h, and, subsequently, for another 4 h with BrdU (BrdU Elisa Kit; Abcam, Milan, Italy). The 
medium was aspirated and cells were incubated with a fixing solution for 30 min. Plates were 
washed three times and the anti-BrdU detector antibody was added for 1 h. Plates were then washed 
a further three times, incubated for 30 min at room temperature with peroxidase goat anti-mouse 
IgG conjugate and then washed three times again. The tetramethybenzidine chromogenic 
peroxidase substrate was added, and plates were incubated for 30 min in the dark. Finally, a stop 
solution was added and the OD450 measured in a plate placed in the Tecan NanoQuant Infinite M200 
Pro reader (Tecan Group Ltd., Männedorf, Switzerland). 
4.5. Soft Agar Colony Formation Assay 
Cells were seeded in flasks and treated with 1 µM ONC for 72 h. Before seeding, Petri dishes 
were prepared with soft agar as follows: 1% low gelling temperature agarose and 2× DMEM 
supplemented with 10% FBS and 1% Antibiotic Antimycotic Solution (Gibco, BRL Invitrogen Corp., 
Carlsbad, CA, USA) were plated at the bottom layer of the plate, while 0.6% agarose and 2× DMEM 
supplemented with 10% FBS and 1% Antibiotic Antimycotic Solution were plated on its top. 
ONC-treated and ONC-free (control) cells were detached, counted and seeded in six-well plates 
(5000 cells/well), together with the upper soft agar solution. 100 µL/well of fresh medium were 
added twice a week and cell colonies were stained with crystal violet after 21 days. Semi-solid 
cultures were performed in triplicate and images were captured with the EVOS FL Auto Cell 
Imaging System (ThermoFischer Scientific, Waltham, MA, USA). 
4.6. Wound Closure Cell Migration Assay 
A375P cells were seeded in six-well plates (2 × 105 cells/well) and, upon reaching confluence, the 
monolayer was scratched with a sterile 200 µL pipette tip. A375DR cells were seeded in six-well 
plates (4 × 105 cells/well) but their monolayer was scratched with a sterile 10 µL pipette tip when 
they reached confluence. To remove detached cells, wells were washed with complete medium and 
afterwards refilled with fresh medium containing 10% FBS. 1 µM ONC was added to this culture 
and samples were compared with the ONC-free ones. A375P cells were incubated for 17 h (1020 
min), while A375DR cells for 54 h (3240 min), and the behavior of both cell subpopulations was 
monitored with EVOS FL Auto Cell Imaging System. Cells were kept at 37 °C in humidified 
atmosphere with 5% CO2 in an EVOS Onstage Incubator (ThermoFisher Scientific, Waltham, MA, 
USA). The A375P cells movement frames were captured every 30 min over the aforementioned 17 h 
with a 5× magnification, while the A375DR cells frames every 2 h with a 10× magnification over the 
aforementioned 54 h, to create time-lapse videos. The relative images were quantitatively analyzed 
with the Image-J computing software and the MRI Wound Healing Tool (NIH, Bethesda, MD, USA). 
In the graphics, the mean value relative to each point calculated from four independent experiments 
is reported ± SD. 
4.7. Transwell Invasion Assay 
Both A375P and A375DR cell subpopulations were incubated for 72 h in the presence or absence 
of 1 µM ONC. Afterwards, cells were detached with trypsin, counted and seeded in a Transwell 
composed of polycarbonate membrane inserts of 8 µm pore size, and coated with a uniform layer of 
a dried basement membrane matrix solution. Cell invasion was measured with the CytoSelectTM cell 
invasion assay kit (CELL BIOLABS, San Diego, CA, USA), according to the manufacturer 
instructions. 0.5 mL of complete medium were added as chemoattractant to the lower chamber well, 
while 0.3 mL of cell suspension consisting of 1 × 106 cells/mL solubilized in DMEM serum-free were 
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seeded on the upper chamber. Invasion capability was analyzed after 48 h: Non-invading cells were 
removed by cotton swab scrubbing, and the invading cells treated with the staining solution. Finally, 
the OD450 was measured in the Tecan NanoQuant Infinite M200 Pro plate reader (Tecan, Männedorf, 
Switzerland). 
4.8. Gelatin Zymography 
Both cell subpopulations were cultured in the presence of absence of ONC for 48 h, and then 
they were serum-starved for 30 h. The conditioned medium was collected and 10× concentrated with 
an Amicon Ultra-2 Centrifugal Filter Unit (Merck-Millipore, Milan, Italy). Protein concentrations 
were determined with Coomassie (ThermoFisher Scientific, Waltham, MA, USA) and samples 
treated with a non-reducing sample buffer. In order to separate proteins, a 7.5% SDS-PAGE was 
performed. The gel contained 4 mg/mL gelatin and was washed with 50 mM Tris-HCl pH 7.5, 5 mM 
CaCl2, and 1 µM ZnCl2 supplemented with 2.5% Triton X-100 (Serva Electrophoresis, Heidelberg, 
Germany). It was then kept in the incubation buffer (1% Triton X-100, 50 mM Tris-HCl pH 7.5, 5 mM 
CaCl2, and 1 µM ZnCl2) for 24 h to allow the digestion by the MMP2 gelatinase. This buffer contained 
the cofactors necessary to maintain the MMP2 gelatinase activity, so that it could degrade the gelatin 
present in the gel. The gel was stained with 0.5% Coomassie Brilliant Blue R-250 in 20% ethanol/10% 
acetic acid, and the gelatinase activity was detected by evaluating presence and intensity of clear 
bands on the blue background. 
4.9. Total and Nuclear Protein Purification 
In order to purify the total protein content, cell pellets were re-suspended in ~50–100 µL of 
RIPA lysis buffer (150 mM NaCl, 5 mM EDTA pH 8.0, 50 mM Tris pH 8.0, 1% NP-40, 0.5% sodium 
deoxycholate, and 0.1% SDS), in the presence of protease and phosphatase inhibitors (Proteoloc 
protease inhibitor cocktails, and phosphatase inhibitor cocktail 2, respectively; Tema Ricerca, 
Bologna, Italy). Samples were incubated on ice for 20 min and centrifuged at 25,000× g for 25 min, at 
4 °C. The supernatant, containing soluble proteins, was collected and maintained at −80 °C until use. 
Nuclear extracts were prepared as described in [55] in the presence of protease and phosphatase 
inhibitors. 
OD relative to protein concentrations were measured at 595 nm by the Coomassie brillant blue 
G-250 Bradford assay in a Jasco V-650 spectrophotometer (Jasco Europe, Cremella (LC), Italy). In 
order to prepare samples for WB analysis, a quarter of the reducing buffer volume (sample buffer: 
625 mM Tris-HCl pH 6.8, 2% SDS, 8% glycerol, 0.25% bromophenol blue, and 5% 
β-mercaptoethanol) and water were added to 40 µg of total protein extract or to 15 µg of nuclear 
protein extract. Samples were then boiled for 3 min and placed on ice to aid in protein denaturation. 
4.10. Quantitative Real Time-PCR Analysis 
RNA was extracted with the Pure link RNA kit (Ambion, Invitrogen Corp., Carlsbad, CA, 
USA), quantified with the Nanodrop UV-vis spectrophotometer (ThermoFisher Scientific, Milan, 
Italy), and its quality checked by agarose gel electrophoresis. Reverse transcription was performed 
(500 ng RNA in 10 µL) by using the SuperScript VILO cDNA synthesis kit (Invitrogen Corp., 
Carlsbad, CA, USA), according to the manufacturer instructions. The expression levels of specific 
genes were determined with RT-qPCR by using the SensiFAST Sybr No-ROX kit (BIOLINE, London, 
UK). In each sample, the gene expression level was normalized to the one of the TATA-box binding 
protein mRNA. PCR reactions were performed in triplicate in a Rotorgene Q (Qiagen, Milan, Italy), 
with the following amplification primers: 
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A comparative quantification of gene expression levels was performed with a Pfaffl’s efficiency 
corrected calculation [56]. 
4.11. WB Assays 
Protein extracts were electrophoresed by a 5–10% polyacrylamide SDS-PAGE, and then 
transferred to a polyvinylidene difluoride membrane (PVDF; Merck-Millipore, Milan, Italy). 
Membranes were blocked at RT with TBST buffer (10 mM Tris-HCl pH 7.5, 100 mM NaCl, and 0.1% 
Tween 20 containing 5% bovine albumin serum (BSA, Serva Electrophoresis GmbH, Heidelberg, 
Germany) for 1 h. Then, they were incubated overnight on a shaker, at 4 °C, with a 5% BSA solution 
containing the primary antibodies for: Cleaved PARP1 (#5625, 1:2000), p65 NF-κB (#8242S, 1:1000), 
p-IKKα/β (Ser176/180) (#2697S, 1:1000), pERK1/2 (#4370S, 1:1000) (Cell Signaling Technology, 
Danvers, CO, USA), β-catenin (GTX101435, 1:5000), N-cadherin (GTX127345, 1:3000), NANOG 
(GTX100863, 1:3000), CD133 (GTX100567, 1:5000) (Genetex, San Antonio, TX, USA), and β-tubulin 
(T8328, 1:2000; Sigma-Aldrich, Milan, Italy). Then, membranes were washed three times with TBST 
buffer for 30 min, then incubated for 1 h with horseradish peroxidase-conjugated secondary 
antibody (anti-rabbit 1:4000, Cell Signaling Technology, Danvers, CO, USA), and washed with TBST 
three times again. All protein extracts were normalized with β-actin protein antibody (#4970, 1:1000; 
Cell Signaling Technology, Danvers, CO, USA). Immuno-detection was carried out with the ECL kit 
(GE-Healthcare, Little Chalfont, UK) and chemiluminescence signals were detected with ChemiDoc 
(Bio-Rad, Hercules, CA, USA). 
 
4.12. Statistics 
All the results are reported as a mean value ± SD. Unless noted otherwise, p values were 
determined using unpaired, two-tailed Student’s t test. For each type of experiment, a minimum of 
three independent biological replicates were performed. 
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